Effects of Xal-Ease on Patient Compliance With Xalatan

N/AUnknownNCT00573638

Augusta University50 enrolled

Overview

The study hypothesis is that the Xal-Ease with increase patient compliance with XALATAN

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Glaucoma

Interventions

Xal-Ease device to be used with Xalatan eye dropsDEVICE

This intervention is a drop instillation guide to be used in conjunction with the FDA approved Xalatan eye drop.

Eligibility

Sex: ALLMin age: 40 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 40 to 80 years old * Diagnosis warranting treatment with Xalatan eye drops. * ambulatory and well functioning Exclusion Criteria: * non-ambulatory * less than 40 or greater than 80 years old * Not using Xalatan eye drops

Locations (1)

Medical College of Georgia Health Inc

Augusta, Georgia, United States

RECRUITING

Outcomes

Primary Outcomes

The primary outcome measure is compliance with the medication XALATAN using and not using the Xal-Ease delivery aid for their glaucoma treatment.

Time frame: six months

Secondary Outcomes

To determine if any of the other factors mentioned in the survey affect compliance to their medical regimen

Time frame: six months

To see whether or not the Xal-Ease device helps patients conserve medication. ie - aids in drops not distilled in the eye.

Time frame: 6 months

Central Contacts

Christian D. Nilson, MD

CONTACT

706-721-1150 cnilson@mail.mcg.edu

Sandra M. Johnson, MD

CONTACT

706-721-1150 sajohnson@mail.mcg.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.